Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zhejiang Jingxin Pharmaceutical is a commercial-stage, listed Chinese pharma company specializing in drugs for psycho-neural and cardiovascular indications, with over 50 marketed drugs and active clinical development in CNS and cardiovascular fields. Significant R&D and international partnerships bolster its innovation pipeline, with strong regulatory track record including FDA and German GMP approvals. It has achieved commercialization of key drugs in China, with pipeline assets in various development phases including Phase II trials for schizophrenia and preclinical programs in Alzheimer's and Parkinson's diseases[1][3][5][4].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zhejiang Jingjin Pharmaceutical.